PaxMedica says research on suramin for autism spectrum disorder to be published

PaxMedica announces that the Annals of General Psychiatry has accepted the manuscript titled “Randomized clinical trial of low dose suramin intravenous infusions for treatment of autism spectrum disorder” for publication. “The acceptance of this manuscript represents a significant milestone in PaxMedica’s continued dedication to pioneering innovative treatments for Autism Spectrum Disorder. We are honored to contribute to the field of psychiatry with this significant research, underscoring our commitment to advancing the understanding and treatment of ASD,” commented Dr. David Hough, Chief Medical Officer at PaxMedica.